- Home
- SST vs VRCA Comparison
SST vs VRCA Comparison
Compare SST & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- VRCA
- Stock Information
- Founded
- SST 2013
- VRCA 2013
- Country
- SST United States
- VRCA United States
- Employees
- SST N/A
- VRCA N/A
- Industry
- SST Diversified Commercial Services
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- SST Consumer Discretionary
- VRCA Health Care
- Exchange
- SST Nasdaq
- VRCA Nasdaq
- Market Cap
- SST 67.8M
- VRCA 58.0M
- IPO Year
- SST N/A
- VRCA 2018
- Fundamental
- Price
- SST $0.46
- VRCA $0.59
- Analyst Decision
- SST Buy
- VRCA Hold
- Analyst Count
- SST 2
- VRCA 5
- Target Price
- SST $3.50
- VRCA $6.00
- AVG Volume (30 Days)
- SST 144.3K
- VRCA 341.5K
- Earning Date
- SST 03-10-2025
- VRCA 03-11-2025
- Dividend Yield
- SST N/A
- VRCA N/A
- EPS Growth
- SST N/A
- VRCA N/A
- EPS
- SST N/A
- VRCA N/A
- Revenue
- SST $343,925,000.00
- VRCA $7,566,000.00
- Revenue This Year
- SST $8.34
- VRCA $93.38
- Revenue Next Year
- SST N/A
- VRCA $127.27
- P/E Ratio
- SST N/A
- VRCA N/A
- Revenue Growth
- SST N/A
- VRCA 47.66
- 52 Week Low
- SST $0.42
- VRCA $0.54
- 52 Week High
- SST $2.73
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- SST 34.30
- VRCA 39.26
- Support Level
- SST $0.45
- VRCA $0.54
- Resistance Level
- SST $0.58
- VRCA $0.68
- Average True Range (ATR)
- SST 0.06
- VRCA 0.07
- MACD
- SST -0.00
- VRCA -0.00
- Stochastic Oscillator
- SST 14.59
- VRCA 22.81
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.